ESMO 2020: Results of a phase I/II study examining CAR T product AUTO3 in combination with pembrolizumab for treatment of relapsed diffuse large b-cell lymphoma.
Home / Resource Library / AUTO3 CAR T-Cell Product Plus Pembrolizumab Shows Clinical Activity, Tolerability in Relapsed/Refractory DLBCL